

Colorado HB 19-1131 Disclosure

NEXLETOL® (bempedoic acid) tablets and NEXLIZET® (bempedoic acid and ezetimibe) tablets.

The following information is provided to Colorado prescribers by Esperion Therapeutics, Inc. in accordance with Colorado House Bill 19-1131.

The pricing information below reflects Esperion’s Wholesale Acquisition Costs for the Esperion product and may not represent actual transactional prices. The price consumers pay for the product may vary from the prices listed below depending upon the availability of discounts and how the consumer purchases the product.

WAC for Esperion Products

Products	NDC	Dosage Form and Strength	Wholesale Acquisition Cost (WAC)
NEXLETOL® (bempedoic acid) tablets	72426-118-03	Bottle of 30	\$407.84
NEXLIZET® (bempedoic acid and ezetimibe) tablets	72426-818-03	Bottle of 30	\$407.84

Source: Medi-Span, 01/01/2023. Reprinted with permission by Wolters Kluwer Clinical Drug Information, Inc. and/or its affiliates. All rights reserved.

Colorado law requires a manufacturer to provide the names of three generic prescriptions drugs that are in the same therapeutic class as Esperion’s product.

Generic Prescription Drugs in the Same Therapeutic Class*

None

Currently, there are no other prescription drugs in the same therapeutic area as NEXLETOL® and NEXLIZET®. Esperion will update this disclosure form should generic drugs become available within the same therapeutic class as NEXLETOL® and NEXLIZET®.

*For purposes of listing generic prescription drugs, the Therapeutic Class is derived from the American Hospital Formulary Service Pharmacologic Therapeutic Classification system, published by the American Society of Health System Pharmacists.

This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries.